The Wegovy dose for weight loss — and why starting low isn't starting wrong

The biggest misunderstanding: higher dose doesn't automatically mean better results

A question our prescribers hear most weeks goes something like this: can I skip ahead, or stay on 0.25 mg and see what happens? Both instincts come from the same place, the assumption that dose and weight loss map neatly onto each other, with more being better and less being pointless. The clinical reality is more nuanced.

The 0.25 mg and 0.5 mg steps are there to let your digestive system adapt. Semaglutide slows gastric emptying and acts on appetite centres in the brain; introduce it too fast and nausea, vomiting or constipation can make the medicine unbearable. Staying at a step longer than four weeks is sometimes the right clinical decision. Rushing past it usually is not.

At the other end, some people find that 1.7 mg produces substantial appetite suppression and significant weight reduction. Moving to 2.4 mg is standard, but the body's response isn't a straight line upward. The STEP 1 trial (published in the New England Journal of Medicine) reported an average loss of around 15% of body weight over 68 weeks at 2.4 mg semaglutide alongside lifestyle changes. That figure is a trial average. Individual results sit above and below it, and individual tolerance shapes how the schedule unfolds.

The short version: the best Wegovy dose for weight loss is the one your prescriber confirms is right for your body, not the one a quick Google suggests, and our page on what the maximum dose of Wegovy means for weight loss explains why that ceiling exists and how it fits into the wider schedule.

What each dose level is actually doing

0.25 mg is a calibration step. Your body meets the medicine; the medicine settles. Side effects are most likely here and in the early weeks, though many people sail through. Weight loss at this stage is minimal, and that is expected.

0.5 mg to 1.0 mg is where appetite suppression becomes more noticeable for most people. You may find portions feel larger, meals feel satisfying earlier, and interest in food between meals drops. Some people begin to see meaningful weight change here.

1.7 mg is the penultimate step before the standard maintenance dose. For adults who experience significant side effects at 2.4 mg, 1.7 mg can serve as a longer-term maintenance level if clinically agreed, the prescriber's call, not the patient's.

2.4 mg is the licensed maintenance dose for weight management in UK adults, and if you want a clearer picture of how each step contributes, our guide to how semaglutide dosing works for weight loss walks through what the evidence shows at each level. You can also read about how weight loss typically differs across each Wegovy dose level in more detail, including what the trial data shows at each step.

The 7.2 mg dose is newer. The MHRA approved it on 14 April 2026 as a single-dose pen for adults with a BMI of 30 or above. Trials reported an average weight loss of around 20.7% over 72 weeks at this dose, which narrows the gap with tirzepatide results considerably. It remains the maximum dose and requires working up through the standard schedule first. Specific availability is confirmed at consultation.

Pausing, missing a dose, and what to do if titration stalls

Life interrupts. A holiday, a busy spell, payday coming later than expected, there are all kinds of reasons someone might miss a dose or pause treatment. The guidance is consistent: if you miss an injection and it has been fewer than five days since it was due, take it as soon as you remember. Beyond five days, skip it and return to your usual schedule the following week. Never take two doses to make up for a missed one.

If a dose increase causes side effects that feel unmanageable, the clinical approach is usually to stay at the previous dose for another four weeks before trying again, rather than stopping altogether. This should always be discussed with your prescriber, not adjusted unilaterally. The full Wegovy dosage guide covers these scenarios in more detail, but for personalised advice your prescriber is the right first call.

Stopping Wegovy entirely tends to result in gradual weight regain, which is why ongoing clinical review matters. It is not a signal of failure, it reflects how the medicine works.

Eligibility for Wegovy and what happens when you reach the maintenance dose

Wegovy is licensed in the UK for adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as high blood pressure or high cholesterol. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. Eligibility for the 7.2 mg dose is restricted to adults with a BMI of 30 or above.

NICE recommends semaglutide for weight management through specialist services for a maximum of two years, with a review at six months to confirm meaningful progress. If fewer than 5% of body weight has been lost on the maintenance dose by that point, continuing is usually not recommended. NICE's appraisal of semaglutide (TA875) sets out the full NHS criteria. Private access has different thresholds, assessed on a case-by-case basis by the prescriber.

At the maintenance dose, clinical review does not stop. At nume, every repeat order is assessed by a GPhC-registered prescriber before it is dispensed. A real clinician reads your answers, not software. If you'd like to explore whether Wegovy is suitable for you, the sensible starting point is an honest conversation with a qualified prescriber. You can find out more about Wegovy and how it works, or if cost is on your mind, our page on what Wegovy actually costs in the UK sets out what an honest private price includes. When you're ready, speak to our prescribers through a free consultation.